A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - August 5, 2025 501 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Olaparib June 27, 2022 Adjuvant Everolimus Does Not Improve Recurrence-Free Survival Among Patients with Renal... August 9, 2023 Alex Trebek Gets Choked Up Seeing Contestant’s Heartfelt ‘Guess’ As Final... November 14, 2019 Appendix Cancers Are Genetically Distinct from Other Gastrointestinal Cancers, Study Shows September 12, 2018 Load more HOT NEWS Lung Cancer Trial of Osimertinib Draws Praise—and Some Criticism Virtual Reality Could Reduce Stress for Chemo Patients, Improving Cancer Outcomes Family Brings Joy & Raises Money With Their Extravagant Christmas Light... Study Finds Light Therapy Helps Radiation-Related Skin Damage Heal 50% Faster
